Ms. Fu has over 18 years of experience in the intellectual property and holds dual educational backgrounds in science and law. Ms.Fu has expertise in patent invalidation, patent administrative and civil litigation, due diligence and FTO of patents, stability analysis of patent rights, and related legal services. , especially in technical areas of Chemistry, pharmaceuticals, medical devices, daily chemical products, chemical materials, and machinery, etc.

She worked at the Beijing Examination and Cooperation Center of CNIPA for 14 years, where she gained relevant work experience in patent substantive examination, reexamination, administrative litigation, patent analysis, and searching.She was awarded honors such as Key Talent of CNIPA, Mentor-level Examiner, and Training Instructor for New Examiners. As a lawyer, she has provided legal services to many domestic and international clients, including Gensci Pharmaceuticals, JNG China, Amperex technology, Corning Incorporated, and Sanofi. The cases she handled were selected as the "TOP TEN Reexamination and Invalidation Cases of 2021," the "Essential Points of Judgments by the Supreme People's Court Intellectual Property Tribunal in 2022," and the "Essential Points of Judgments by the Supreme People's Court Intellectual Property Tribunal in 2024." She was also honored as an "Outstanding Lawyer in Pharmaceutical Intellectual Property" by the IP Frontier.

Ms. Fu was licensed to practice as a Chinese Patent Attorney in 2009 and passed the National Judicial Examination in 2019.

Lung Tin Law Firm, Patent Attorney, Attorney at Law

Beijing Patent Examination Cooperation Center of the CNIPA, Patent Examiner

Master of law, China University of Political Science and LAW, in Civil and commercial law

Master of Science, Chinese Academy of Medical Sciences & Peking Union Medical College, in Pharmaceutical Chemistry

Bachelor of Science, Shenyang Pharmaceutical University, in Traditional Chinese Medicine

Nanjing CHIA TAI TIANQING v. ACTELION Pharmaceuticals patent invalidation,

TAI TIANQING v.Eisai R&D  Pharmaceuticals patent invalidation,

Jiangnan Environmental Protection v. Jiangsu COHEN series patent invalidation,

Sichuan Kelun v. Hardwood drug companies Pharmaceuticals patent invalidation,

Simcere Pharmaceutical Group v. AMGEN INC Pharmaceuticals patent invalidation,

Qilu Pharmaceutical  v.BAYER Pharmaceuticals patent invalidation,

CSPC Pharmaceutical Group v.Boehringer Ingelheim INT Pharmaceuticals patent invalidation,

Qilu Pharmaceutical  v.BAYER drug-patent linkage administrative adjudication,

Huahai Pharmaceutical v. Dainippon Sumitomo Pharma drug-patent linkage litigation

Author, "Current Operation and Countermeasures of the Early Resolution Mechanism for Drug Patent Disputes After the Involved Patent Is Declared Invalid," October 2022, Intellectual Property Finance

Author, "A Review and Analysis of the P-IV Declarations Under China's Drug-Patent Linkage System Since Its Implementation," December 2022, Intellectual Property Power

Author, “Overview of patent challenges about pharmaceutical compound (1)-(4)”, 2021-2023, Lung Tin WeChat Article

Author, “An Analysis of the Stay Period for Drug-Patent Linkage System in China Law”, October 2020 Issue, Lung Tin WeChat Article

Author, “The Subtlety and Complexity of Drug-Patent Linkage System-in Sight from the Mova and Mylan Litigation ”, August 2020, Lung Tin WeChat Article

Speaker, “Intellectual Property Protection of Pharmaceutical Enterprises from the Perspective of Drug Registration Management Reform”, Symposium on Drug Related Intellectual Property Protection, June 2020, Beijing, China

Author, “Paper Examples in US Patents and the Enlightenment for China's Patent Practice,” China Intellectual Property, September 2019

Author, "Fake Technology" in Traditional Chinese Medicine Patent Applications and Examination Considerations," Intellectual Property Studies, 2018

Author, "Competition Between Originator and Generic Drug Companies: A Case Study of the Olmesartan Patent," Chinese Journal of New Drugs, 2015

Author, "Analysis of Chinese Patent Applications for Ginkgo Biloba Drugs," Chinese Invention and Patents, 2011